Camurus_®

Improving treatments for patients with severe and chronic diseases



Jefferies London Healthcare Conference 16 November 2022

Forward looking statements

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance.

Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus' ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases.

Camurus undertakes no obligation to update forward-looking statements.

Camurus snapshot

Rapidly growing commercial stage company

Leader in opioid dependence treatment with Buvidal weekly and monthly depots

Strong financial performance

Entering profitability in 2022



Advancing late-stage pipeline with blockbuster potential

Prospects for multiple new approvals in coming years in CNS and rare disease indications

Unique FluidCrystal[®] technology platform

Commercially validated, with a broad range of applications

LISTED ON NASDAQ STOCKHOLM TICKER CAMX; EMPLOYEES: ~170

camurus

camurus

Significant recent progress



Positive financial development

- ✓ High double-digit year-on-year revenue growth
- ✓ Entering profitability in 2022
- ✓ Robust cash position no debt



Commercialization execution

- Leader in long-acting opioid dependence treatment in the EU and Australia
- ✓ Strong sales growth, supported by an expanding evidence base
- ✓ Further potential through label and geographic expansion




Pipeline advancement

- ✓ Successful life-cycle management
- ✓ Key programs in registration phase in the US, EU and Australia
- ✓ Four ongoing Phase 3 studies in rare disease indications
- Significant potential in early-stage programs and technology platform developments

camurus

Strong quarterly financial development






Revenue growth **+57%** vs Q3 2021

Operating result +48 MSEK vs Q3 2021

Cash position SEK 520 million +22% vs Q3 2021

camurus

On track for full year profitability



FY 2022 outlook

Total revenue **SEK 900 to 950 million**

Product sales **SEK 875 to 925 million**

Operating results SEK 40 to 70 million (increased from SEK –60 to 10 million)





"It is absolutely amazing. Almost everything is as before."

Martin, Buvidal patient, Sweden

camurus

Buvidal – game changing opioid dependence treatment

Weekly and monthly, subcutaneous buprenorphine for individualized treatment of opioid dependence¹

Opioid dependence a global health crisis

- Largest burden of all drugs
- Est 80,000 overdose deaths in the US alone

Buvidal has significant benefits vs. standard daily treatment

- Superior treatment outcome and patient satisfaction²⁻⁵
- Blockade of subjective opioid effects from first dose³
- Reduced treatment burden and improved quality of life^{5,6}
- Decreased risk of diversion, misuse and pediatric exposure^{7,8}

¹ SmPC Buvidal May 2021; ²Lofwall et al. JAMA Int. Med. 2018;178(6); 764-773; ³Walsh et al, JAMA Psychiatry 2017;74(9);894-902; ⁴Frost , M., et al. Addiction. 2019;114(8):1416-1426. <u>doi:10.1111/add.14636;</u> ⁵Lintzeris, N., et al. JAMA Network Open. 2021;4(5):e219041. <u>doi:10.1001/jamanetworkopen.2021.9041</u>, ⁶Barnett et al Drug and Alcohol Dependence 2021; <u>https://doi.org/10.1016/j.drugalcdep.2021.108959</u>; ⁷EPAR for Buvidal; ⁸Dunlop, A. J., et al. Addiction. 2021. <u>https://doi.org/10.1111/add.15627</u>;

Buvidal sales growth underscores potential

Leadership in opioid dependence treatment

- High double-digit year-on-year sales growth
- Buvidal available in 18 countries in Europe, Australia and the Middle East
- Est. >32,000 patients in treatment end of Q3
- Passed milestone of >1 million sold Buvidal units since launch


Significant additional potential in geographic expansion

- Recent market approvals in Egypt and Saudi Arabia
- Tentative approval in the US. Waiting for US licensee Braeburn to resubmit Brixadi¹ NDA for final approval. Launch exp. 2023
- Additional five national regulatory applications under review

Indication expansion to chronic pain

- Market authorization applications under review in EU and Australia

Quarterly product sales



Broad and diversified mid- to late-stage pipeline

Phase 1	Phase 2	Phase 3	Registration
CAM2043 Pulmonary arterial hypertension	CAM2029 Polycystic liver disease	CAM2029 Acromegaly	Brixadi ™ Opioid use disorder (US)¹
CAM2047 Chemotherapy-induced nausea and vomiting	CAM2032 Prostate cancer	CAM2029 Gastroenteropancreatric neuroendocrine tumors	CAM2038 Chronic pain (EU, AUS)
CAM2048 Postoperative pain	CAM2043 Raynaud's phenomenon	CAM4072 Genetic obesity disorders ²	
CAM4071 Endocrine disorders			CNSRare diseasesOncology & supportive care



CAM2029 – octreotide subcutaneous depot in Phase 3 development

Octreotide SC depot under assessment in three, serious rare disease indications

- Acromegaly
- Gastroenteropancreatic neuroendocrine tumors (GEP-NET)

camurus

• Polycystic liver disease (PLD)

Designed for enhanced efficacy and patient convenience



CAM2029 targeting 3 billion dollar SSA market


SSAs established treatment with limitations

- First-line treatment of acromegaly and neuroendocrine tumors (NET)
- Established safety and efficacy profile
- However, complex administration and modest response


CAM2029 best-in-class treatment potential

- Convenient self-administration with state-of-the-art pen device
- Enhanced SSA exposure (500% bioavailability increase)
- Potential for improved disease control and treatment outcomes





CAM2029 extensive clinical program



Timelines are indicative. PK – pharmacokinetic; PD – pharmacodynamic; RCT – Randomized control trial; LST – Long-term safety trial; ACRO – acromegaly, GEP-NET – gastroenteropancreatic neuroendocrine tumors; PLD – polycystic liver disease; OLE – open label extension

CAM2029 recent and upcoming milestones



- ✓ Two Phase 3 trials ongoing
- Recruitment completed in pivotal efficacy trial (RCT)
- □ Topline results mid 2023
- □ Long-term safety results H2 2023
- Est. NDA/MAA submissions 2023/24



- Phase 3 SORENTO trial ongoing, largest randomized NET study
- Est. completion of patient recruitment mid 2023
- Topline results after 194 PFS events
- Est. NDA/MAA submissions 2025



- ✓ Orphan drug designation (US)
- New PROs developed and aligned with FDA
- ✓ Phase 2b POSITANO trial ongoing
- Est. completion of patient enrollment in H1 2023
- □ Topline efficacy results H1 2024



SORENTO

Subcutaneous Octreotide Randomized Efficacy in Neuroendocrine TumOrs



POlycystic liver Safety and efflcacy TriAl with subcutaNeous Octreotide

Key priorities going forward

Grow and strengthen market leading position of Buvidal

camurus

- Expand to new markets and indications
- Advance R&D Pipeline to new approvals
- 1-00-55
- Diversify business through partnering and M&A
- 0
 - On track to sustainable profitability



Camurus ABIdeon Science Park, SE-223 70 Lund, SwedenP +46 46 286 57 30info@camurus.comcamurus.comcamurus.com



Experienced and committed management team



Shareholders and analyst coverage

Shareholders as of 31 October 2022	Number of shares	% of capital	% of votes
Sandberg Development AB	21,875,692	39.5	39.5
Fjärde AP-fonden	3,502,450	6.3	6.3
Avanza Pension	2,401,362	4.3	4.3
Didner & Gerge Fonder	2,332,561	4.2	4.2
Fredrik Tiberg, CEO	1,680,000	3.0	3.0
State Street Bank and Trust	989,490	1.8	1.8
JP Morgan Chase Bank	904,612	1.6	1.6
Svenskt Näringsliv	892,851	1.6	1.6
Backahill Utveckling	826,491	1.5	1.5
Lancelot Avalon	750,000	1.4	1.4
Öhman Fonder	587,940	1.1	1.1
Afa Försäkring	560,460	1.0	1.0
Camurus Lipid Research Foundation	495,250	0.9	0.9
Handelsbankens fonder	467,691	0.8	0.8
Carl-Olof och Jenz Hamrins Stiftelse	425,000	0.8	0.8
Other shareholders	16,691,597	30.1	30.1
In total	55,383,447	100.0	100.0



Analysts

Carnegie Erik Hultgård

DNB Patrik Ling

Handelsbanken Suzanna Queckbörner Mattias Häggblom

Jefferies James Vane-Tempest

Nordea Viktor Sundberg

Pareto Peter Östling

Brixadi well positioned against competition

	ONSE-MONTHLY	T T (Weekly/Monthly
Long-acting injectables features	Sublocade [®]	Vivitrol	Buvidal.
Weekly dosing	-	_	✓
Monthly dosing	\checkmark	√	✓
Multiple doses	_	_	\checkmark
Choice of inj. sites	-	_	✓
Smallest needle	(19G)	(20G)	🗸 (23G)
Lowest dose volume	0.5–1.5mL	3.4mL	✓ 0.16–0.64mL
Room temp. storage	-	_	\checkmark
Day one initiation	_	_	\checkmark
Clin. Data vs active control*	_	_	\checkmark
Launched	US, CAN, AUS, IL	US	EU, UK, AUS

AcroInnova program for CAM2029 in acromegaly

Pivotal randomized, placebo-controlled Phase 3 trial


- Rigorous, 24-week, randomized, double-blind, placebo-controlled trial
- Primary endpoint biochemical response (IGF-1≤1xULN)
- Filling regulatory requirement for efficacy

Long-term safety Phase 3 trial

- 52-week long-term safety, switch and extension trial
- Endpoints include safety (primary), IGF-1, GH and PROs (QoL)
- Filling regulatory requirements for safety exposure



- Two Phase 3 trials ongoing
- Recruitment finalized in Phase 3 efficacy trial
- ✓ Long-term safety trial extended with additional 12-month period
- □ Phase 3 efficacy results mid-2023
- Est. NDA and MAA submissions 2023/24




SORENTO program for CAM2029 in NET

Multinational, randomized, active-controlled Phase 3 trial

- Primary endpoint is superiority in progression free survival, PFS, versus octreotide LAR and lanreotide ATG
- Assessed after 194 progression events
- Multiple patient reported outcomes included in study
- Single, large trial fulfilling regulatory requirements for safety and efficacy
- Broad GEP-NET population of grade 1 to grade 3

SORENTO



SORENTO

Subcutaneous Octreotide Randomized Efficacy in Neuroendocrine TumOrs

- ✓ SORENTO Phase 3 trial ongoing
- ✓ >25% patients enrolled
- Est. enrollment completion mid-2023
- Completion SORENTO efficacy part after 194 PFS events
- Estimated NDA/MAA submissions 2025


POSITANO program for CAM2029 in PLD

Significant unmet need with no approved treatment

- PLD is a rare, genetic and chronic disorder
- Progressive growth of cysts in the liver, can cause severe symptoms
- Estimated ~30,000 patients with symptomatic PLD¹
- No approved medical treatment increased scientific evidence for SSA's

POSITANO trial to assess efficacy and safety

- 52-week randomized, placebo-controlled, three-arm trial
- Primary endpoint is liver volume change
- Key secondary endpoint Camurus' developed PROs, PLD-S



PLD – polycystic liver disease, SSAs – somatostatin analogues ; PRO – patient reported outcome ; PLD-S – PLD symptoms ¹Globe Life Science 2020,



POlycystic liver Safety and effIcacy TriAl with subcutaNeous Octreotide

- ✓ Orphan drug designation (US)
- New PROs developed and aligned with FDA
- ✓ Phase 2b trial started June 2022
- Planned enrollment completion mid-2023
- □ Topline results 2024

Significant market potential for CAM2029

Attractive opportunity

ACRO

- Highly concentrated target audiences

TERRITORY

EU/AUS

- Differentiated product properties
- Switch opportunity from established first-line treatments

CAM2029 peak sales estimates from third party market research¹⁻⁴

PATIENT

POPULATION

 $16,500^4$

US 10,000 25 - 40%\$150 – 280 million EU/AUS 68,000⁴ 30% €300 – 400 million NET US 37,000 40% \$1,200 – 1,500 million EU/AUS 15-18,000⁴ 30 - 40%€80 – 100 million **PLD**¹ US 12-13,000 30 - 40%\$200 – 300 million

EST. PEAK

PATIENT SHARE

20 - 35%

EST. PEAK SALES

€30 – 65 million





[?] Top selling drug to enter the market will be Camurus' Octreotide LA[?]

Estimates CAM2029 sales of **US\$210m** US+EU5 sales in 2029 in acromegaly

Other rare disease opportunities

Setmelanotide SC depot, CAM4072

- Developed by license partner Rhythm
- Positive PK and PD results in Phase 2a MAD study
- Phase 3 trial ongoing in switch patients with genetic obesity disease, e.g. Bardet Biedl Syndrome (BBS)
- □ Topline Phase 3 results expected in 2023
- Second Phase 3 trial in naïve patients planned to start in H1 2023
- □ Camurus eligible to milestones and royalty payments

Treprostinil SC depot, CAM2043

- Targeting high medical need in treating Raynaud's Phenomenon and PAH
- Recent Phase 2a results indicate efficacy in Raynaud's Phenomenon¹
- Evaluations of next steps ongoing

Significant change in Raynaud's condition score (95% Cl)

